Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2-positive Solid Tumors
NCT02500199Phase 1Unknown
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2015
- Primary completion
- May 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of pyrotinib in breast cancer, gastric cancer (GC), non-small cell lung cancer (NSCLC) and 1 more (3 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Maximum Tolerated Dose and Overall Response Rate up to 24 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancergastric cancer (GC)non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT02500199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500199.